Esperion Therapeutics, Inc. - stock earnings
ESPR Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 7, 2024 BeforeMarket | - / 0.0502000000 | - | - / 86.2 million | - |
ESPR Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -56.3 million USD | 32.3 million USD |
| 2023Q3 | -41.3 million USD | 34.0 million USD |
| 2023Q2 | -49.9 million USD | 25.8 million USD |
| 2023Q1 | -89.2 million USD | 24.3 million USD |
| 2022Q4 | -68.5 million USD | 18.8 million USD |
| 2022Q3 | -68.6 million USD | 19.0 million USD |
| 2022Q2 | -80.3 million USD | 18.8 million USD |
| 2022Q1 | -70.5 million USD | 18.8 million USD |
| 2021Q4 | -65.1 million USD | 15.4 million USD |
| 2021Q3 | -69.4 million USD | 14.4 million USD |
| 2021Q2 | -43.7 million USD | 40.7 million USD |
| 2021Q1 | -90.9 million USD | 8.0 million USD |
| 2020Q4 | -104.5 million USD | 9.6 million USD |
| 2020Q3 | -85.4 million USD | 3.8 million USD |
| 2020Q2 | 124.6 million USD | 212.2 million USD |
| 2020Q1 | -78.2 million USD | 1.8 million USD |
| 2019Q4 | -61.9 million USD | 982000 USD |
| 2019Q3 | -68.4 million USD | 981000 USD |
| 2019Q2 | -54.2 million USD | 982000 USD |
| 2019Q1 | 87.4 million USD | 145.4 million USD |
| 2018Q4 | -60.0 million USD | 184.5 million USD |
| 2018Q3 | -49.9 million USD | ? USD |
| 2018Q2 | -45.7 million USD | ? USD |
| 2018Q1 | -46.1 million USD | ? USD |
| 2017Q4 | -37.9 million USD | ? USD |
| 2017Q3 | -45.2 million USD | ? USD |
| 2017Q2 | -43.3 million USD | ? USD |
| 2017Q1 | -40.5 million USD | ? USD |
| 2016Q4 | -29.0 million USD | ? USD |
| 2016Q3 | -17.4 million USD | ? USD |
| 2016Q2 | -14.0 million USD | ? USD |
| 2016Q1 | -14.6 million USD | ? USD |
| 2015Q4 | -13.1 million USD | ? USD |
| 2015Q3 | -12.8 million USD | ? USD |
| 2015Q2 | -12.4 million USD | ? USD |
| 2015Q1 | -11.5 million USD | ? USD |
| 2014Q4 | -9.5 million USD | ? USD |
| 2014Q3 | -9.8 million USD | ? USD |
| 2014Q2 | -9.2 million USD | ? USD |
| 2014Q1 | -7.9 million USD | ? USD |
| 2013Q4 | -9.7 million USD | ? USD |
| 2013Q3 | -5.2 million USD | ? USD |
| 2013Q2 | -6.9 million USD | ? USD |
| 2013Q1 | -4.2 million USD | ? USD |
| 2012Q4 | -2.8 million USD | ? USD |
| 2012Q3 | -3.4 million USD | ? USD |
| 2012Q2 | -3.2 million USD | ? USD |
| 2012Q1 | -2.4 million USD | ? USD |
| 2003Q3 | -6.6 million USD | ? USD |
| 2003Q2 | -8.4 million USD | ? USD |
| 2003Q1 | -7.4 million USD | ? USD |
| 2002Q4 | -6.6 million USD | ? USD |
| 2002Q3 | -7.0 million USD | ? USD |
| 2002Q2 | -7.8 million USD | ? USD |
| 2002Q1 | -7.3 million USD | ? USD |
| 2001Q4 | -6.3 million USD | ? USD |
| 2001Q3 | -6.3 million USD | ? USD |
| 2001Q2 | -6.3 million USD | 1000 USD |
| 2001Q1 | -6.0 million USD | 1000 USD |
| 2000Q4 | -5.6 million USD | 1000 USD |
| 2000Q3 | -10.8 million USD | 1000 USD |
| 2000Q2 | -6.5 million USD | 1000 USD |
| 2000Q1 | -4.7 million USD | ? USD |
ESPR Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -209.2 million USD | 116.3 million USD |
| 2022 | -287.8 million USD | 75.5 million USD |
| 2021 | -318.8 million USD | 78.4 million USD |
| 2020 | -166.2 million USD | 227.5 million USD |
| 2019 | -109.0 million USD | 148.4 million USD |
| 2018 | -201.8 million USD | 184.5 million USD |
| 2017 | -167.0 million USD | ? USD |
| 2016 | -75.0 million USD | ? USD |
| 2015 | -49.8 million USD | ? USD |
| 2014 | -36.4 million USD | ? USD |
| 2013 | -26.1 million USD | 5.0 billion USD |
| 2012 | -11.7 million USD | ? USD |
| 2011 | -10.8 million USD | ? USD |
| 2002 | -28.7 million USD | ? USD |
| 2001 | -24.9 million USD | ? USD |
| 2000 | -27.6 million USD | 2000 USD |
| 1999 | -10.7 million USD | ? USD |
ESPR
Price: $2.12
52 week price:
Earnings Per Share: -2.03 USD
P/E Ratio: -1.14
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 623424
Ebitda: -37.8 millionMarket Capitalization: 465.4 million